,i #aadth ,,congress #b;d ,session ,h4 ,r4 #eief ,,in ,,the ,,house ,,of ,,representatives ,september #h1 #bjaf,ms4 ,clark of ,massachusetts 7for herself and ,mr4 ,bucshon7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend the ,public ,health ,service ,act to better address substance use and substance use disorders among young people4 #a4 ,short title ,this ,act may be cited as the ,youth ,opioid ,use ,treatment ,help ,act of #bjaf or the ,,youth ,act4 #b4 ,reauthorization of substance abuse treatment services for children and adolescents 7a7 ,in general ,section #ead of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bij;bb-#g7 is amended-- 7#a7 by striking abuse and inserting use each place it appears2 7#b7 by striking children and adolescents and inserting children1 adolescents1 and young adults each place it appears2 and 7#c7 in subsection 7f71 by striking for fiscal years #bjjb and #bjjc and inserting for each of fiscal years #bjag through #bjbb4 7b7 ,technical correction ,section #ead of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #bij;bb-#i71 as added by section #cfcb of the ,methamphetamine ,anti-,proliferation ,act of #bjjj 7,public ,law #ajf-caj2 #aad ,stat4 #abcf71 is redesignated as section #ead;,b4 #c4 ,access to medication-assisted treatment for adolescents and young adults demonstration program 7a7 ,in general ,the ,secretary of ,health and ,human ,services1 acting through the ,director of the ,agency for ,healthcare ,research and ,quality 7in this section referred to as the ,director71 shall award grants to eligible entities to establish demonstration programs to-- 7#a7 expand access to medication-assisted treatment for opioid use disorders among adolescents and young adults2 7#b7 identify and test solutions to overcoming barriers to implementation of medication-assisted treatment for adolescents and young adults2 or 7#c7 create and distribute for pediatric health care providers resources on medication-assisted treatment training and implementation4 7b7 ,eligible entities ,to be eligible to receive a grant under subsection 7a71 an entity shall-- 7#a7 be a ,state1 political subdivision of a ,state1 ,indian tribe1 tribal organization1 professional pediatric provider organization1 professional addiction medicine provider1 hospital1 an institution of higher education1 or other appropriate public or nonprofit institution2 and 7#b7 certify that it is in compliance with all applicable registration and licensing requirements4 7c7 ,application ,to seek a grant under this section1 an entity shall submit to the ,director an application at such time1 in such manner1 and containing such information as the ,director may require4 7d7 ,duration ,an eligible entity may receive funds under this section to carry out a demonstration program described in this section for a period of not greater than #c years4 ,after the first year for which funding is provided to an eligible entity for a demonstration program1 funding may be provided under this section for a subsequent year for such program only upon review of such program by the ,director and approval by the ,director of such subsequent year of funding4 7e7 ,reports 7#a7 ,by grant recipients ,each eligible entity awarded a grant under this section for a demonstration program shall submit to the ,director progress reports on such demonstration program at such times1 in such manner1 and containing such information as the ,director may require4 7#b7 ,by ,director ,not later than one year after the date on which all demonstration programs funded under this section have been completed1 the ,director shall submit to the ,committee on ,health1 ,education1 ,labor1 and ,pensions of the ,senate1 and the ,committee on ,energy and ,commerce of the ,house of ,representatives a report that-- 7,a7 describes the availability of medication-assisted treatment for adolescents and young adults with opioid use disorders in the ,united ,states1 including barriers to such treatment2 7,b7 describes the specific demonstration programs carried out pursuant to this section2 7,c7 evaluates the effectiveness of such programs2 7,d7 evaluates any unintended consequences of such programs2 and 7,e7 provides recommendations for ensuring that medication-assisted treatment is accessible to adolescents and young adults with opioid use disorders4 7f7 ,definitions ,in this section3 7#a7 ,the phrase adolescents and young adults means individuals who have attained #aj years of age and not yet attained #bf years of age4 7#b7 ,the term medication-assisted treatment means pharmacological treatments approved by the ,food and ,drug ,administration1 in combination with counseling and behavioral therapies4 7#c7 ,the term opioid use disorder means a substance use disorder that is a problematic pattern of opioid use leading to clinically significant impairment or distress occurring within a #ab-month period4 7#d7 ,the term pediatric health care provider means a provider of health care to individuals who have attained #aj years of age and not yet attained #bf years of age4 7#e7 ,the term professional pediatric provider organization means a national organization whose members consist primarily of pediatric health care providers4 7g7 ,authorization of appropriations ,there is authorized to be appropriated #e1jjj1jjj to carry out this section4 #d4 ,,gao study and report on programs and research relative to substance use and substance use disorders among adolescents and young adults 7a7 ,study ,the ,comptroller ,general of the ,united ,states shall conduct a study on how ,federal agencies are addressing prevention of1 treatment for1 and recovery from substance use by and substance use disorders among adolescents and young adults4 ,such study shall include an analysis of each of the following3 7#a7 ,the research that has been1 and is being1 conducted or supported by the ,federal ,government on prevention of1 treatment for1 and recovery from substance use by and substance use disorders among adolescents and young adults1 including an assessment of-- 7,a7 such research relative to any unique circumstances 7including social and biological circumstances7 of adolescents and young adults that may make adolescent-specific and young adult-specific treatment protocols necessary1 including any effects that substance use and substance use disorders may have on brain development and the implications for treatment and recovery2 and 7,b7 areas of such research in which greater investment or focus is necessary relative to other areas of such research4 7#b7 ,the ,federal non-research programs and activities that address prevention of1 treatment for1 and recovery from substance use by and substance use disorders among adolescents and young adults1 including an assessment of the effectiveness of such programs and activities in preventing substance use by and substance use disorders among adolescents and young adults1 treating such adolescents and young adults in a way that accounts for any unique circumstances faced by adolescents and young adults1 and supports long-term recovery among adolescents and young adults4 7#c7 ,gaps that have been identified by ,federal officials and experts in ,federal efforts relating to prevention of1 treatment for1 and recovery from substance use by and substance use disorders among adolescents and young adults1 including gaps in research1 data collection1 and measures to evaluate the effectiveness of ,federal efforts1 and the reasons for such gaps4 7b7 ,report ,not later than #b years after the date of enactment of this ,act1 the ,comptroller ,general shall submit to the appropriate committees of the ,congress a report containing the results of the study conducted under subsection 7a71 including-- 7#a7 a summary of the findings of the study2 and 7#b7 recommendations based on the results of the study1 including recommendations for such areas of research and legislative and administrative action as the ,comptroller ,general determines appropriate4